prostatic acid phosphatase-sargramostim fusion protein PA2024
Term · Oncology and biomedicine · MLC-T-ONC-016254
A genetically-engineered protein formed by the fusion of prostatic acid phosphatase (PAP) and sargramostim (GM-CSF). Vaccination with antigen-presenting cells (APC) loaded with prostatic acid phosphatase-sargramostim fusion protein may elicit a cytotoxic T-cell response against tumor cells that express PAP.
| Identifier | MLC-T-ONC-016254 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | PA2024; prostatic acid phosphatase-sargramostim fusion protein |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-016254",
"term": "prostatic acid phosphatase-sargramostim fusion protein PA2024",
"field": "Oncology and biomedicine",
"definition": "A genetically-engineered protein formed by the fusion of prostatic acid phosphatase (PAP) and sargramostim (GM-CSF). Vaccination with antigen-presenting cells (APC) loaded with prostatic acid phosphatase-sargramostim fusion protein may elicit a cytotoxic T-cell response against tumor cells that express PAP.",
"synonyms": [
"PA2024",
"prostatic acid phosphatase-sargramostim fusion protein"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/prostatic-acid-phosphatase-sargramostim-fusion-protein-pa2024/"
}
Record 13,734 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.